These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9855414)

  • 1. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring and safety assessment in Phase I to III clinical trials.
    Fescharek R; Nicolay U; Arras-Reiter C
    Dev Biol Stand; 1998; 95():203-9. PubMed ID: 9855433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.
    Kamath AT; Fruth U; Brennan MJ; Dobbelaer R; Hubrechts P; Ho MM; Mayner RE; Thole J; Walker KB; Liu M; Lambert PH; ;
    Vaccine; 2005 May; 23(29):3753-61. PubMed ID: 15893612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging studies.
    Fritzell B
    Dev Biol Stand; 1998; 95():181-8. PubMed ID: 9855430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
    Cohen J; Benns S; Vekemans J; Leach A
    Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring protection: efficacy versus effectiveness.
    Fedson DS
    Dev Biol Stand; 1998; 95():195-201. PubMed ID: 9855432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S; Nilsson B; Mellstedt H
    Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The quest for an HIV vaccine].
    Girard MP
    Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological factors in clinical trial design.
    Wassilak S
    Dev Biol Stand; 1998; 95():75-83. PubMed ID: 9855417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.